Holen Sie sich die Stockscreener-App
2.77
5.32%
0.14
Schlusskurs vom Vortag:
$2.63
Offen:
$2.7501
24-Stunden-Volumen:
37,351
Relative Volume:
0.16
Marktkapitalisierung:
$1.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.03M
KGV:
-0.0223
EPS:
-124.0371
Netto-Cashflow:
$-6.53M
1W Leistung:
-7.05%
1M Leistung:
-29.52%
6M Leistung:
-67.83%
1J Leistung:
+0.00%
1-Tages-Spanne:
$2.70
$2.9453
1-Wochen-Bereich:
$2.63
$3.04
52-Wochen-Spanne:
$2.63
$16.92
Decoy Therapeutics Inc Stock (DCOY) Company Profile
Firmenname
Decoy Therapeutics Inc
Sektor
Branche
Telefon
346-772-0346
Adresse
2450 HOLCOMBE BLVD, HOUSTON
Compare DCOY vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DCOY
Decoy Therapeutics Inc
|
2.77 | 1.72M | 0 | -13.03M | -6.53M | -124.04 |
VRTX
Vertex Pharmaceuticals Inc
|
521.28 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.12 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.40 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.12 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-23 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-04-27 | Eingeleitet | Ladenburg Thalmann | Buy |
Decoy Therapeutics Inc Aktie (DCOY) Neueste Nachrichten
Decoy Therapeutics CEO to present antiviral dru... - Pluang
Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference - TMX Newsfile
Decoy Therapeutics Grants 3,900 Shares to Chief Business Officer Marschel Peter Klaus - Kalkine Media
Decoy Therapeutics Grants 2,000 Shares to Insider Gauthier Patricia G. at No Cost on August 31, 2026 - Kalkine Media
Director at Decoy Therapeutics (DCOY) awarded 2,000 restricted shares vesting in 2027 - Stock Titan
Decoy Therapeutics (DCOY) awards CEO 33,455 restricted shares - Stock Titan
Decoy Therapeutics (DCOY) awards CBO stock at $0 per share - Stock Titan
Decoy Therapeutics (DCOY) CFO granted multi-year stock award - Stock Titan
Chief scientist at Decoy Therapeutics (DCOY) gets 4,216-share stock grant - Stock Titan
Decoy Therapeutics (DCOY) director gets 3,000-share stock grant - Stock Titan
Director at Decoy Therapeutics (DCOY) granted 2,000 shares vesting in 2027 - Stock Titan
Director at Decoy Therapeutics (DCOY) gets 2,000-share grant vesting in 2027 - Stock Titan
Decoy Therapeutics (DCOY) awards 3,000 $0.00 shares to director - Stock Titan
Director at Decoy Therapeutics (DCOY) granted 2,000 restricted shares - Stock Titan
Moody Capital Solutions - TMX Newsfile
Decoy (DCOY) Results Check: EPS Prints Above Forecast in the Current Update; Post-Earnings: The Stock Records a 2.81% DecreaseRevenue Guidance Range - vinanet.vn
ARMISTICE CAPITAL, LLC Acquires Shares of Decoy Therapeutics Inc (DCOY) - GuruFocus
Decoy (DCOY) Latest Quarter: The Available Earnings Metric Delivers a Beat on the Day; After Earnings: Shares Rise 0.29% in the Latest SessionRevenue Guidance Range - vinanet.vn
Decoy (DCOY) Trading Levels Update: Adds 1.14% to Close at $3.56 for the Current Session; Chart Reference - vinanet.vn
DCOY Q3 2024 Earnings: Narrower Loss of -136.8 per Share Delivers Positive SurpriseCash Flow Report - vinanet.vn
Decoy Therapeutics (DCOY) Advances 1.42% to $3.58, Holding Above SupportCTA Positioning - vinanet.vn
Armistice Capital (DCOY) discloses 65,503-share, 9.99% holding in Decoy Therapeutics - Stock Titan
DCOY Q2'26 Earnings: EPS estimate is (2.88) USD - TradingView
Decoy Therapeutics: Q2 Earnings Snapshot - Barchart.com
Decoy Therapeutics: Q2 Earnings Snapshot | Associated Press | syndication news - Enidnews.com
Decoy Therapeutics Inc. Q2 2026: Revenue $0.23M, Net loss $(2.37M), EPS $(4.46) — 10-Q Summary - TradingView
Decoy Therapeutics (DCOY) posts wider Q2 loss, flags going-concern and Nasdaq risks - Stock Titan
Decoy Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
DCOY Q3 2024 Earnings: Loss Narrows Sharply, Delivering 68.95% Positive EPS SurpriseGuidance Accuracy Score - vinanet.vn
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform - Morningstar
Decoy Therapeutics expands IP portfolio to 19 applications By Investing.com - Investing.com Nigeria
Decoy Therapeutics expands IP portfolio to 19 applications - Investing.com
Decoy Therapeutics (DCOY) Holds Firm Above $4 as Traders Eye Key Resistance at $4.32MFI Overbought - dars.gov.et
DCOY Q3 2024 Earnings: Loss Narrows Sharply, Beating Estimates by 68.95%Earnings Trend Analysis - vinanet.vn
DCOY Q3 2024 Earnings: Narrower-Than-Expected Loss of -136.8 per Share Highlights Cost DisciplineROA Comparison - vinanet.vn
DCOY Q3 2024 Earnings: Loss Narrower Than Expected as Cost Controls Take EffectShort-Term Outlook - Vinanet
Decoy Therapeutics (DCOY) Advances Research on D-MAV Candidates for Filoviruses - GuruFocus
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAVtm Platform into High Consequence Global Health Threats - Lelezard
Decoy Therapeutics’ D-MAV platform shows inhibition of Ebola Zaire virus - TipRanks
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats - Morningstar
Decoy candidate shows activity against Ebola and Lassa in tests - Stock Titan
Lead D-MAV shows activity against Ebola, expanding Decoy Therapeutics' antiviral platform to filovirus threats. - Pluang
Decoy Therapeutics Inc. Revenue Breakdown – MUN:FP11 - TradingView
DCOY Q3 2024 Earnings: Narrower Loss Surprises; Pre-Revenue Stage Remains FocusEarnings Acceleration Picks - vinanet.vn
Decoy Therapeutics (DCOY) pursues warrant approvals and cuts authorized shares - Stock Titan
Decoy Therapeutics Inc. (NASDAQ: DCOY) Share Price, DCOY Stock News, DCOY Share Price & Updates - Kalkine
Decoy Therapeutics Inc. Revenue Breakdown – FWB:FP11 - TradingView
Decoy Therapeutics (DCOY) Rallies 1.42% as Shares Test Key Resistance at $5.24ETF Flow - dars.gov.et
Decoy Therapeutics Inc. SEC Filing (Jul 20, 2026) - Stock Titan
$5.86 | Decoy Therapeutics Inc. Common Stock (DCOY) Stock Price Today - Binance
DCOY Q3 2024 Earnings: Narrower-Than-Expected Loss Fails to Lift Sentiment as Stock Slides 10%Revenue Inflection Point - vinanet.vn
Finanzdaten der Decoy Therapeutics Inc-Aktie (DCOY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Decoy Therapeutics Inc-Aktie (DCOY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HANISH ARNOLD C | Director |
Dec 30 '25 |
Sale |
0.64 |
12 |
8 |
0 |
| HANISH ARNOLD C | Director |
Nov 20 '25 |
Buy |
0.75 |
5,000 |
3,740 |
5,015 |
| Rosenblum Mark J | Exec VP Finance, CFO |
Nov 20 '25 |
Buy |
0.80 |
20,000 |
16,000 |
20,177 |
0.69%
3.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):